Celldex’s Cdx-622 Shows Promise in Preclinical Inflammatory Disease Study
Celldex Therapeutics announced positive preclinical data for CDX-622, a bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and stem cell...
NKgen Biotech Administers First Troculeucel Dose to Stroke Patient
NKGen Biotech administered its expanded autologous NK cell therapy, troculeucel, to a stroke patient under an FDA-cleared compassionate use...
Oryzon Defines Phase III Trial Endpoints for Agitation & Aggression in BPD
Oryzon Genomics has established primary and key secondary endpoints for its Phase III clinical trial of vafidemstat for Borderline...
Spectral Medical’s Tigris Trial Update
Spectral Medical Inc. (TSX: EDT) announced an update on its Tigris Phase 3 trial, which is evaluating Polymyxin B...
MBX Biosciences Completes Avail™ Phase 2 Trial Enrollment
MBX Biosciences completed enrollment in its Phase 2 Avail™ trial of canvuparatide, a parathyroid hormone (PTH) prodrug for chronic...
Transforming Oncology with Real World Data: Insights from COTA’s Miruna Sasu
In this conversation with Miruna Sasu, President and CEO of COTA Healthcare, we explore the transformative power of real...
Aura Biosciences NMIBC Data at EAU Congress
Aura Biosciences announced Phase 1 data from its trial of bel-sar (AU-011) for non-muscle invasive bladder cancer (NMIBC) will...
Voyager Reports Positive Topline Anti-Tau Antibody Data, Initiates Next Trial
Voyager Therapeutics announced positive topline data from its single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody...
Traws Pharma Reports Positive Bird Flu Results for Tivoxavir
Traws Pharma announced positive topline results from a ferret study of tivoxavir marboxil, a single-dose oral antiviral for bird...
Deucrictibant Data at AAAAI/WAO 2025: HAE Prevention & Treatment
Pharvaris released positive long-term data for its oral bradykinin B2 receptor antagonist, deucrictibant, at the 2025 AAAAI/WAO Joint Congress....